Esbriet and Evista drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Esbriet (pirfenidone) and Evista (raloxifene hydrochloride). Common drug interactions include nausea among females.

The phase IV clinical study analyzes what interactions people have when they take Esbriet and Evista. It is created by eHealthMe based on reports of 13 people who take the same drugs from the FDA, and is updated regularly.

What is Esbriet?

Esbriet has active ingredients of pirfenidone. eHealthMe is studying from 39,858 Esbriet users. Check the latest studies of Esbriet.

What is Evista?

Evista has active ingredients of raloxifene hydrochloride. It is often used in osteoporosis. eHealthMe is studying from 25,891 Evista users. Check the latest studies of Evista.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 01, 2026

13 people who take Esbriet and Evista together, and have interactions are studied.

What are the common drug interactions of Esbriet and Evista, by gender? *:

female:

Nausea (feeling of having an urge to vomit)
Decreased appetite
Sinusitis (inflammation of sinus)
Abdominal discomfort
Ephelides (tanned macules found on the skin)
Hypopnoea (decrease in the breathing rate)
Insomnia (sleeplessness)
Oedema (fluid collection in tissue)
Respiratory disorder (respiratory disease)
Transient ischaemic attack (a transient episode of neurologic dysfunction caused by ischemia (loss of blood flow))

male:

n/a

What are the common drug interactions of Esbriet and Evista, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

n/a

50-59:

n/a

60+:

Nausea (feeling of having an urge to vomit)
Back disorder
Insomnia (sleeplessness)
Oedema (fluid collection in tissue)
Respiratory disorder (respiratory disease)
Transient ischaemic attack (a transient episode of neurologic dysfunction caused by ischemia (loss of blood flow))
Abdominal discomfort
Abdominal pain upper
Headache (pain in head)
Shock (a life-threatening condition with symptoms like low blood pressure, weakness, shallow breathing, cold, clammy skin)

What are the existing conditions these people have? *

Idiopathic Pulmonary Fibrosis (chronic lung disease): 13 people, 100.00%
Nausea (feeling of having an urge to vomit): 2 people, 15.38%
High Blood Cholesterol: 2 people, 15.38%
Stress And Anxiety: 1 person, 7.69%
Irritable Bowel Syndrome: 1 person, 7.69%
Hypersensitivity: 1 person, 7.69%
Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 1 person, 7.69%
Atrial Fibrillation/flutter (atrial fibrillation and flutter are abnormal heart rhythms in which the atria, or upper chambers of the heart, are out of sync with the ventricles): 1 person, 7.69%

* Approximation only. Some reports may have incomplete information.

Do you take Esbriet and Evista?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously